Introduction
Cachexia is a multi-factorial metabolic syndrome characterized by weight loss due to depletion of muscle with or without loss of fat (1) . Systemic inflammation, insulin resistance, enhanced muscle protein breakdown and sympathetic nervous system activation are hallmarks of cachexia. A plethora of diseases are associated with cachexia, e.g. chronic infections (HIV, tuberculosis), chronic heart failure, chronic obstructive lung disease and chronic kidney failure (2) . The most common association, however, exists between cachexia and cancer, where it can occur in up to 80% of cases (3) . Cancer-associated cachexia (CAC) goes along with unfavorable prognosis and plays a causal role in up to 20% of cancer-related deaths (3) . CAC is unresponsive to nutritional support and while a lot of progress has been made in the past years regarding the mechanisms of CAC, an effective treatment option is still missing.
Patients suffering from hepatocellular carcinoma (HCC) typically show loss of muscle mass and strength (termed sarcopenia), resulting in frailty and debilitating physical weakness (4) . In addition, cachexia is a common characteristic of HCC patients which not only reduces the quality of life, but -together with sarcopenia-impacts significantly on overall prognosis (5) and clinical decision making: Mortality of HCC patients after intra-arterial therapy (6) and liver transplantation (7) as well as dose-limiting toxicities of sorafenib (8) , which is the gold standard oral treatment for non-resectable HCC, are independently predicted by sarcopenia. Taken together, cachexia and sarcopenia are of pivotal importance for both patients (quality of life, prognosis) and clinicians (progression, treatment decision).
Against this background, a better understanding of the molecular and cell biological mechanisms that govern HCC-associated sarcopenia and cachexia is urgently needed. As cachexia is a multi-factorial syndrome affecting various organs and cellular systems, this can only be achieved by using in vivo model systems that recapitulate the syndrome as a whole (9) . With respect to HCC-associated cachexia, the most widely applied system is the rat ascites hepatoma Yoshida AH-130 model. This is characterized by a hypercatabolic state and marked depletion of both skeletal muscle and adipose tissue (10, 11) . While the Yoshida AH-130 model is certainly of great value, especially for the identification of potential cachexia-inhibiting drugs (12, 13) , a better understanding of the pathogenesis of HCC-associated cachexia is limited by the absence of a practicable murine model system. Intercrossing such a mouse model with conventional or cell type-specific knock-out mice would enable researchers to address a number of hypotheses and would undoubtedly result in a much better understanding of the molecular and cell biological mechanisms that govern HCC-associated cachexia (14) .
Here, we describe a robust cachexia phenotype in a transgenic murine HCC model. Intercrosses with mice harboring defective myeloid cell-mediated inflammation unexpectedly resulted in enhanced cachexia-associated loss of adipose tissue even though systemic levels of proinflammatory cytokines were lower in the knock-out mice. Furthermore, we present experimental data arguing for a protective role of macrophages in the context of CAC-associated fat loss.
Taken together, our results challenge the general understanding of pro-inflammatory cytokines as causal agents of CAC and establish a functional importance of macrophages in the setting of CAC-associated fat loss that has not been previously appreciated.
Results

ASV-B mice display robust cancer-associated cachexia
The transgenic ASV-B mouse line is a well-established HCC model based on hepatocytespecific expression of the SV40 large T oncogene (15) . In this model, mice develop dysplastic hepatocytes at 8, hepatic adenomas at 12 and hepatocellular carcinomas at 16 weeks of age (16) . We initially evaluated the HCC progression by measuring liver weight in different age groups. As shown in figure 1A , liver weight of ASV-B mice strongly increased with age compared to tumor-free C57BL/6J controls, reflecting tumor progression. Rather unexpectedly, this pronounced increase of liver mass did not affect total body weight. In fact, ASV-B mice were even slightly lighter than tumor-free C57BL/6J mice between 12 and 18 weeks of age ( Fig. 1B ).
Food and water intake were not different between control and HCC-bearing mice, ruling out a functional relevance of anorexia in this setting (Fig. 1C) . Altogether, the observed phenotype led us to consider tissue wasting and cachexia in the course of ASV-B tumor formation. To address this, we initially evaluated the mass of different skeletal muscle regions. As can be seen in figure   1D , tumor-bearing mice showed a significant decrease in mass of gastrocnemius (GC), tibialis anterior (TA) and extensor digitorum longus (EDL) muscle over time. Furthermore, heart weight was diminished in ASV-B compared to tumor-free mice in all age groups ( Fig. 1D ). Along with the muscle wasting, we observed a striking loss of adipose tissue in tumor-bearing mice.
Measurement of gonadal fat depots revealed that fat loss started at 12 weeks of age and continued throughout tumor progression ( Fig. 1E) . A representative image of an ASV-B mouse at the age of 16 weeks shows visibly smaller gonadal fat depots and clear tumor nodules in the massively enlarged liver (Fig. 1F ). The loss of adipose tissue and muscle mass illustrates the development of cancer-associated cachexia (CAC) in ASV-B mice.
Defective myeloid cell-mediated inflammation unexpectedly aggravates loss of adipose tissue in HCC-bearing mice
Systemic inflammation is widely appreciated as a driving force of cachexia (17) . Myeloid cells, e.g. granulocytes, monocytes and macrophages, are the chief cellular effectors of the innate immune system and centrally involved in cancer-associated inflammation (18) . Earlier work by us and others has identified the hypoxia-inducible transcription factor HIF-1 as an essential regulator of myeloid cell-mediated inflammation (19) . We sought to investigate the functional importance of myeloid cells for the pathogenesis of CAC in ASV-B mice. To this end, we intercrossed ASV-B mice with myeloid cell-specific Hif1a knock-out mice (termed ASV-B/Hif1a MC ) and analyzed body weight and body composition. As can be seen in figure 2A , ASV-B/Hif1a MC mice displayed a non-significant tendency for higher body weight than WT mice. Body composition analysis by nuclear magnetic resonance (NMR) spectroscopy showed a lower amount of total body fat in ASV-B/Hif1a MC mice, again without reaching statistical significance ( Fig. 2B ). In addition to NMR analyses, in vivo micro computed tomography (µCT) imaging of mice was performed to visualize and quantify body composition. 2D cross-sectional images and three-dimensional volume renderings of segmented bones, lungs, liver and fat were obtained. In figure 2C , representative µCT images display fat loss in all depots as well as liver enlargement in tumor-bearing mice. Quantification of the volume analysis indicated a significant decrease of fat amount in ASV-B mice compared to controls (Fig. 2D ). The total fat amount in ASV-B/Hif1a MC mice tended to be lower than in ASV-B WT mice (significance level of 0.05, Fig. 2D ), which is consistent with the obtained NMR body composition results. Of note, skeletal muscle and heart weight did not differ between ASV-B WT and ASV-B/Hif1a MC mice (Suppl. Fig. 1 ). Taken together, the defective myeloid cell-mediated inflammation did not result in reduced CAC, but unexpectedly aggravated the CAC-associated fat loss.
Visceral adipose tissue of ASV-B mice displays typical cachexia-associated changes
We sought to identify the mechanisms underlying the loss of visceral adipose tissue (VAT) in ASV-B mice and addressed the hypothesis that enhanced lipid mobilization takes place in HCCbearing mice (20, 21) . To this end, we quantified the cell size of adipocytes in epididymal white adipose tissue (eWAT) and could show substantial cell shrinking between control and ASV-B mice (Fig. 3A) . ASV-B/Hif1a MC mice had a higher frequency of smaller adipocytes (<1.500 µm 2 ) and lower frequency of relatively larger adipocytes (1.500-4.000 µm 2 ) than ASV-B WT mice (statistically significant at 2.000 µm 2 ) (Suppl. Fig. 2 ). It recently became clear that white adipose tissue (WAT) is able to switch to a thermogenic fat burning phenotype (termed "browning") (22) . This process was found to contribute to the increased energy expenditure typical for cachexia in different mouse models of cancer cachexia (22, 23) . We found significantly elevated mRNA levels of various browning marker genes in WAT of ASV-B mice in comparison to tumor-free controls ( Fig. 3B ), demonstrating WAT browning in this HCC model. Of note, myeloid cellspecific deletion of Hif1a did not impact on browning marker gene expression in WAT ( Fig. 3B ).
Next, we focused on lipolysis of adipose tissue and performed an ex vivo lipolysis assay from eWAT. This assay allowed us to measure the secretion of glycerol from eWAT explants and demonstrated that ASV-B/Hif1a MC mice mobilize fat more efficiently than ASV-B WT mice ( Fig.   3C ). Finally, we checked whether serum levels of triglycerides were increased. Here, under ad libitum food intake conditions, triglyceride levels were found elevated in ASV-B mice compared to controls. However, ASV-B WT and Hif1a MC mice exhibited similar triglyceride levels ( Fig. 3D ).
Neither tumor load, pro-inflammatory cytokine expression nor hypothalamic activation underlie the enhanced fat loss in ASV-B/Hif1a MC mice
Having confirmed the unexpected aggravation of cancer-associated VAT loss in ASV-B/Hif1a MC mice, we next sought to identify the underlying mechanism(s). One obvious explanation would be an effect of the myeloid cell-specific Hif1a deletion on HCC formation, as we have observed for intestinal tumors (24) . However, neither µCT-based quantification of liver volume ( Fig. 4A ), gross liver weight, nor histology-based measurements of tumor load ( Fig. 4B ) displayed a difference between WT and ASV-B/Hif1a MC mice. As the hypothalamus is able to control lipid uptake and mobilization in WAT (25), we analyzed the activation state of neurons in the nucleus arcuatus (ARC) of the hypothalamus (26) . Figure 4C shows the number of c-Fos positive (+) cells in the ARC, reflecting the level of recent neuronal activation. The numbers of c-Fos+ cells in HCC-bearing mice are significantly increased, arguing for an elevated activation of the ARC.
As the sympathetic nervous system (SNS) has been shown to mediate the effects of the hypothalamus on WAT (27), we measured catecholamine levels in peripheral fat tissue and found a significant increase in ASV-B compared to tumor-free mice (results for noradrenaline shown in Fig. 4D , adrenaline was not detectable). Again, myeloid cell-specific Hif1a deletion remained without a significant effect in these experiments. In adipose tissue, macrophages were suggested as an alternative source of catecholamines (28) , although contradictory findings were published in later reports (29) . Of note, we were not able to detect noradrenaline or adrenaline in supernatants from bone marrow-derived macrophages from WT and Hif1a MC mice, arguing that macrophages are not a likely source for catecholamines in adipose tissue. Next, we stained eWAT for tyrosine hydroxylase (TH), a marker of sympathetic neurons, the cells that synthesize catecholamines in their axons. Quantitative differences were observed neither between control and ASV-B mice nor between ASV-B WT and Hif1a MC mice ( Fig. 4E, F ). Finally, we determined serum levels of pro-inflammatory cytokines, which have been shown in numerous studies to be positively associated with cachexia (30, 31) . Tumor necrosis factor α (Tnf-α), interleukin 6 (Il-6) and interleukin 1β (Il-1β) are the best studied pro-inflammatory cytokines among these and they can be secreted by macrophages (17) . ASV-B WT mice showed significantly increased serum levels of Il-6, Il-1β and Tnf-α compared to tumor-free control mice ( Fig. 4G ). What's more, serum levels of Il-1β were significantly reduced while Il-6 and Tnf-α showed a tendency for decrease in ASV-B/Hif1a MC mice. Collectively, these results suggest a functional interplay of pro-inflammatory cytokines and the hypothalamus-peripheral sympathetic nervous system axis in regulating tumor-associated lipolysis in ASV-B mice.
Abundance of adipose tissue macrophages is controlled by Hif1a
Macrophages have been shown to be important for adipose tissue homeostasis and can be recruited to and accumulate in adipose tissue after lipolysis, where they take part in local lipid regulation (32) . Against this background, we characterized different biological aspects of adipose tissue macrophages (ATM) in ASV-B mice. As it was shown that alternatively activated macrophages (AAMs) predominate under conditions of lipid mobilization (33), we decided to analyze macrophage polarization in our model. We applied different experimental approaches, none of which showed a significant effect of Hif1a deletion on polarization of adipose tissue macrophages ( Fig. 5A, B ). Next, we determined ATM abundance via immunohistochemistry against F4/80. Interestingly, while a significant increase in ATM number was noted in ASV-B WT animals, this was completely inhibited upon Hif1a deletion (Fig. 5C ). Finally, we sought to address a possible contribution of ATM proliferation in our setting. As can be seen in figure 5D , loss of Hif1a resulted in a significant decrease of Ki67-positive ATMs, arguing for a functional importance of HIF-1α for ATM proliferation that has not been previously appreciated.
Quantification of visceral adipose tissue in human HCC patients
The robust fat loss of ASV-B mice raised the question about the relevance of this phenotype for the human situation. To this end, we made use of a cohort of HCC patients (n=41, patient characteristics are given in materials and methods) without underlying liver cirrhosis as the ASV-B model is also not associated with hepatic fibrosis (15) . Interestingly, 34% of the patients indeed displayed low visceral adipose tissue as determined by the L3 VAT index ( Fig. 6 ). Low L3
VAT index was significantly associated with low body mass index (P < 0.001), young age (P = 0.017) and female sex (P = 0.027), while no association was found with tumor stage.
Discussion
Clinical care of patients with hepatocellular carcinoma is characterized by various challenging obstacles. Co-morbidities of chronic liver disease, limited resectability due to cirrhosisassociated reduction of functional liver reserve and the stout therapy resistance of HCC are among the most widely recognized impediments. For the longest time, the frailty and pronounced muscle weakness that characterizes the majority of HCC patients received much less attention. This has significantly changed in recent years as reports were published from independent groups about the important role of sarcopenia and cachexia in predicting clinical course and response to therapy of HCC patients (4, (34) (35) (36) . Cachexia is widely considered to be a multi-factorial syndrome with various manifestations throughout the whole body. The causal pathogenesis of cachexia is very complex and involves a plethora of organs, cell types, hormones, cyto-/chemokines, growth factors and interorgan crosstalks (37, 38) . To better understand the molecular and cell biological mechanisms that govern cachexia, model systems are needed that recapitulate the syndrome on a whole organism level (39) .
Here, we identify a robust cachexia phenotype in the well-established ASV-B mouse HCC model (40) . Various characteristic aspects of cachexia were noted in ASV-B mice, e.g. loss of skeletal and heart muscle as well as adipose tissue mass over time, enhanced pro-inflammatory cytokine expression in blood, anemia (Suppl. Fig. 3 ) and weight loss. While a number of animal models are available to study cancer-associated cachexia (41) , only one is widely used with respect to HCC-associated CAC: The rat ascites hepatoma Yoshida AH-130 model (42) . This model proved of great value to test the anti-cachexia efficacy of various agents in vivo. However, it does not adequately mirror the pathogenesis of HCC as its heterotopic nature does not reflect the liver microenvironment. Furthermore, the AH-130 cells have been established more than 60 years ago (43) and it is reasonable to assume that since then they have acquired a lot of additional changes with unknown relevance for HCC pathogenesis. Recently, it was reported by the group of Erwin Wagner that 50% of mice harboring DEN (di-ethyl-nitrosamine)-induced HCCs developed signs of cachexia at 16-18 months of age (22) . While this is a very interesting finding that significantly expands the models available to study HCC-associated CAC, the long time span in combination with a penetrance of 50% are surely obstacles against widespread use of this model. Against this background it is important to note that in ASV-B mice, we were able to detect signs of cachexia with 100% penetrance as early as 12 weeks of age. We therefore consider the ASV-B model to be a powerful addition to the available methodology enabling a better understanding of the mechanistic underpinnings that underlie HCC-associated CAC.
Loss of adipose tissue is a well-known aspect of cancer-associated cachexia and has been noted in animal models as well as samples from patients with various types of cancer (44) . It has been reported that adipose tissue loss precedes muscle wasting (45) and that inhibition of the former is able to slow down the latter (14) . Reduced peripheral fat content in CAC can be the result of three different processes in adipocytes: Lipid uptake, intracellular de novo lipogenesis and lipid release (3) . Our finding of visceral adipose tissue wasting in ASV-B mice is well in line with various other murine CAC models (44) and also with the rat hepatoma Yoshida AH-130 model (11) . To the best of our knowledge, we are the first to report a functional significance of macrophages for HCC-associated fat loss. Intercrosses of ASV-B with mice showing defective myeloid cell-mediated inflammation resulted in aggravated fat loss. Via immunohistochemistry we could show greater macrophage abundance in AT from wildtype tumor-bearing mice while this phenotype was completely inhibited in KO mice. This led us to hypothesize that HCCinduced AT mobilization results in macrophage influx, ultimately inhibiting lipid release. This would be well in line with earlier reports showing macrophage-mediated suppression of lipid mobilization from AT in response to fasting and pharmacologically induced lipid release in mice (46) . Greater macrophage numbers have also been reported in adipose tissue of patients with CAC (47), underscoring the need to better understand the functional significance of these cells for cancer cachexia.
To analyze the role of macrophages for HCC-associated cachexia we made use of a mouse model displaying a defect in myeloid cell-mediated inflammation (19) . This is achieved by conditional deletion of Hif1a in cells of late myeloid differentiation via the Cre/loxP system (48) .
Hif1a encodes for the transcription factor hypoxia-inducible factor 1α (HIF-1α), the principle mediator of the cellular response to hypoxia (49) . HIF-1α target genes control virtually all aspects of the hypoxic response, e.g. erythropoiesis, angiogenesis, glucose metabolism and cell cycle modifications. Inactivation of Hif1a in myeloid cells severely impairs energy generation, leading to robustly compromised cellular function and defective myeloid cell-mediated inflammation (19) . Our finding of reduced macrophage infiltration into adipose tissue during HCC-associated cachexia is well in line with earlier findings by us and others, demonstrating impaired chemotaxis and migration of Hif1a-deficient macrophages, neutrophils and eosinophils in a wide range of underlying pathologies (19, 50) . The important question as to the molecular stimuli that attract macrophages to adipose tissue in HCC-bearing mice remains to be addressed in the future. Published work points towards adipocyte-secreted chemokines, e.g.
MCP-1/CCL2, and free fatty acids (FFAs) (46, 51) . Of note, expression of the MCP-1 receptor CCR2 on monocytes (52) and signal transduction induced by TLR4 (53), the putative cellular receptor for FFAs (54) , are strongly influenced by HIF-1α, potentially explaining the reduced macrophage abundance in adipose tissue upon Hif1a deletion. In addition to macrophage abundance, our results show reduced proliferation of adipose tissue macrophages in conditional Hif1a knock-out mice. While local proliferation of macrophages has been shown in adipose tissue inflammation associated with obesity (55), we are the first to report local macrophage proliferation in the setting of CAC-associated fat loss. Furthermore, a functional role of HIF-1α for macrophage proliferation has thus far only been reported for bovine macrophages after infection with the parasite Theileria annulata (56) and not for murine myeloid cells. Admittedly, the percentage of local macrophages that proliferate is rather small. Hence, the functional significance of this observation for CAC-induced lipolysis remains elusive and needs to be validated in future studies.
In line with the mouse model data we were able to show that a subgroup of HCC patients displays a reduced amount of visceral adipose tissue. This strongly suggests that HCC is also capable of inducing fat mobilization from peripheral stores in human patients. To prove this convincingly, one would have to perform longitudinal patient studies, i.e. analyzing the same patient at different stages of disease progression, a venture out of scope of the current project.
In other cancer types, e.g. pancreatic adenocarcinoma, adipose tissue loss is a well-known phenomenon with clinical relevance as it is able to predict survival (57) . The functional importance of adipose tissue loss for the clinical course of HCC needs to be addressed by future studies with larger patient cohorts. In light of the leading role of adipose tissue loss for the sequence of events characterizing cancer cachexia (14) , a better understanding of the mechanisms driving HCC-associated fat mobilization is warranted.
Materials and Methods
Animals
Hepatocyte-specific expression of the SV40 large T oncoprotein in ASV-B mice was achieved by the antithrombin III promoter (15) . Only male mice develop tumors as the transgene is located 
Statistical Analysis
The statistical analyzes of data were carried out with Student's t-test or by One-Way ANOVA, 
Supplementary Materials and Methods
Organ harvest
ASV-B mice were sacrificed at the age of 12, 16, and 18 weeks. 16 week old C57BL/6J male mice were used as control for tissue weights. Blood serum, liver, epididymal white adipose tissue (eWAT), skeletal muscle (gastrocnemius (GC), soleus, tibialis anterior (TA) and extensor digitorum longus (EDL), and heart were collected and weighed after sacrifice.
Body weight and composition
Body weight, food and water intake were measured weekly. Body composition was analyzed via nuclear magnetic resonance (NMR) spectroscopy device EchoMRI-700™ (Echo Medical Systems, Houston, TX) once a week to measure total body fat and lean mass.
In vivo µCT Imaging
In vivo µCT imaging of normal C57BL/6, ASV-B WT and ASV-B Hif1a MC mice was performed using a dual-energy gantry-based flat-panel microcomputed tomography scanner (TomoScope 30s Duo, CT Imaging, Erlangen, Germany). The dual-energy X-ray tubes of the µCT were operated at voltages of 40 and 65 kV with currents of 1.0 and 0.5 mA, respectively.
To cover the entire mouse, three sub-scans were performed, each of which acquired 720 projections with 1032 × 1012 pixels during one full rotation with durations of 90 s. Animals were sacrificed just before imaging. After acquisition, volumetric data sets were reconstructed using a modified Feldkamp algorithm with a smooth kernel at an isotropic voxel size of 35 µm. The fat-containing tissue regions, which appear hypo-intense in the µCT data, were segmented using an automated segmentation method with interactive correction of segmentation errors (1) . The volumetric fat percentage was computed as the ratio of (subcutaneous and visceral) fat volume to the entire body volume.
Immunohistochemistry and tissue analysis
Mice were sacrificed and tissues were fixed in 10% formalin overnight, followed by dehydration and embedding in paraffin. For histopathological evaluation, two-micrometerthick eWAT or liver sections were stained with hematoxylin and eosin (H&E). For adipose tissue, pictures of representative areas from each section in 200x magnification were taken and Adiposoft software was used to calculate cell size of 35 images per group in total.
Minimal 20 µm and maximum 100 µm thresholds were set for automated measurement of adipocyte diameter followed by manual correction. A frequency distribution was calculated for each group. Total adipocyte number within the distribution was subsequently calculated and the frequency was converted to a percentage of total adipocytes counted. For analyses of tumor areas, H&E stained sections of ASV-B livers were used. Two tissue sections per mouse were used for evaluation. Images were taken using Axiocam 506 mono (Carl Zeiss) and tumor areas were quantified by ImageJ. 
Immunohistochemistry of murine hypothalamus
